8-K: Entera Bio and OPKO Health Collaborate to Develop Oral GLP-1/Glucagon Tablet for Obesity and Metabolic Disorders

Entera Bio and OPKO Health have entered into a collaboration and license agreement to develop an oral GLP-1/glucagon dual agonist tablet for treating obesity and metabolic disorders.

Summary

• Entera Bio and OPKO Health are collaborating to develop an oral GLP-1/glucagon dual agonist tablet using Entera's N-Tab technology and OPKO's oxyntomodulin analog (OPK-88006).
• The collaboration aims to create a once-daily oral treatment for obesity, metabolic, and fibrotic disorders.
• OPKO and Entera will hold 60% and 40% pro-rata ownership interests, respectively, and will be responsible for 60% and 40% of the program's development costs, respectively.
• OPKO purchased 3,685,226 ordinary shares of Entera at $2.17 per share, totaling $8.0 million, to fund Entera's share of Phase 1 development costs.
• After Phase 1, Entera can opt-out, retaining a 15% ownership interest, with OPKO holding 85% and fully funding further development.
• The companies anticipate filing an Investigational New Drug (IND) application with the FDA later in 2025.
• The agreement includes exclusivity provisions, preventing both companies from independently pursuing similar programs during a specified period.

Sentiment

Score: 8

Explanation: The document conveys a positive outlook due to the collaboration between two companies, the potential of the new oral treatment, and the financial investment from OPKO. The agreement's structure also provides Entera with flexibility in managing its financial commitment.

Positives

• The collaboration combines Entera's oral delivery technology with OPKO's long-acting oxyntomodulin analog.
• The oral tablet formulation offers a potentially more convenient treatment option for patients.
• The agreement includes an option for Entera to reduce its financial commitment while retaining a portion of the program's proceeds.
• OPKO's investment provides Entera with funding for its share of initial development costs.
• The collaboration leverages the expertise of both companies in drug development and commercialization.

Negatives

• Entera will be responsible for 40% of the programs development costs.
• Entera's ownership stake decreases to 15% if it opts out of funding after Phase 1.
• The success of the program depends on the successful development and regulatory approval of the oral tablet.

Risks

• Clinical trials may not be successful, and the FDA may not approve the oral tablet.
• Development costs may exceed the estimated budget.
• The collaboration agreement could be terminated under certain circumstances.
• The companies may face competition from other treatments for obesity and metabolic disorders.
• Material Safety Issues could arise with respect to the Collaboration Product.

Future Outlook

The companies plan to advance the oral GLP-1/glucagon dual agonist tablet into clinical trials, with an IND filing expected later in 2025, aiming to provide a new treatment option for obesity and metabolic disorders.

Management Comments

• Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO, stated the goal is to provide additional options for patients with obesity, metabolic and fibrotic diseases.
• Miranda Toledano, Entera Chief Executive Officer, said the collaboration reinforces their shared vision to develop first in class differentiated oral peptide treatments.

Industry Context

The collaboration addresses the growing market for obesity and metabolic disorder treatments, with a focus on developing a convenient oral formulation as an alternative to injectable therapies. Currently, there are no approved dual GLP-1/Glucagon agonists available.

Comparison to Industry Standards

• Novo Nordisk's Ozempic and Wegovy are examples of GLP-1 receptor agonists that have achieved significant commercial success in the treatment of diabetes and obesity, respectively, but are administered via injection.
• Eli Lilly is developing a dual GLP-1/GIP receptor agonist, tirzepatide (Mounjaro), which has shown promising results in clinical trials for both diabetes and obesity, but is also an injectable.
• The collaboration between Entera and OPKO aims to differentiate their product by offering an oral formulation, which could improve patient compliance and convenience compared to injectable therapies.

Related Party Transactions

• OPKO's purchase of 3,685,226 ordinary shares of Entera for $8.0 million is a related party transaction.

Stakeholder Impact

• Shareholders of both Entera Bio and OPKO Health may benefit from the potential success of the collaboration.
• Patients with obesity, metabolic, and fibrotic disorders could gain access to a new, more convenient treatment option.
• Employees of both companies may have opportunities to work on the development and commercialization of the oral tablet.

Next Steps

• File an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA).
• Initiate clinical trials to evaluate the safety and efficacy of the oral GLP-1/glucagon dual agonist tablet.
• Further develop and optimize the formulation and manufacturing process for the oral tablet.
• Explore potential commercialization strategies and partnerships.

Key Dates